GDTC CytoMed Therapeutics Ltd: Multiplikator forward rega marang pendapatan
CytoMed Therapeutics (GDTC) is optimizing cell product trials through external contractors to minimize internal risks. The projected P/S valuation reflects current market dynamics, where the value 39.90 captures the metric level. Fundamentals rely on NK-therapy developments for oncology and the strong scientific expertise of the Singapore-based management, which effectively allocates resources for early-stage clinical trials.
GDTC (w2.cytomed.sg): rincian analitis lan laporan miturut indikator
- rega saham lan target rega konsensus:
- data kapitalisasi saham perusahaan:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal CytoMed Therapeutics|GDTC - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal CytoMed Therapeutics Limited|GDTC - Utang agregat perusahaan|Utang marang nilai buku CytoMed Therapeutics Limited|GDTC - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan CytoMed Therapeutics|Rasio cepet w2.cytomed.sg
- data bathi bisnis lan rasio investasi:
GDTC - Bathi pungkasan|Proyeksi bathi mangsa ngarep CytoMed Therapeutics|GDTC - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep CytoMed Therapeutics Limited|GDTC - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA CytoMed Therapeutics Limited|GDTC - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan CytoMed Therapeutics|GDTC - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan w2.cytomed.sg|GDTC - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep CytoMed Therapeutics
- rincian pendapatan lan dodolan:
Pambiji fundamental perusahaan:CytoMed (GDTC)
Forward P/S compares the current market value of a business with projected future sales, allowing an investor to assess the extent of the premium paid for expected revenue growth rates. For CytoMed Therapeutics (GDTC), which is currently in the safety validation stage of its bio-platform, the expected price-to-sales ratio serves as an indicator of market confidence in the potential of future pharmaceutical alliances, confirming the fundamental resilience of the development strategy.
Pesaing wigati
BeiGene - Multiplikator forward rega marang pendapatan|Halozyme Therapeutics, Inc. (HALO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Corp - Rasio rega marang pendapatan sing dikarepake|CG Oncology, Inc. (CGON) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep urogen.com (URGN)|Rasio rega marang prakiraan pendapatan Bicara Therapeutics|Multiplikator forward rega marang pendapatan Personalis Inc (PSNL)|Multiplikator Forward P/S ERAS|DCTH - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S YMAB (Y-mAbs Therapeutics)|AURA: Kapitalisasi marang prakiraan pendapatan|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc)|SLS (sellaslifesciences.com) - Multiplikator forward rega marang pendapatan|ACTU: Rasio rega marang pendapatan sing dikarepake|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|HURA: Rega forward marang dodolan|Multiplikator Forward P/S TARA|FATE - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Aadi Bioscience WHWK|Rega forward marang dodolan TCRX|Champions Oncology Corp - Multiplikator Forward P/S|XBIT - Multiplikator Forward P/S|cel-sci.com (CVM) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan OSTX (OS Therapies Inc.)|RADX (Radiopharm Theranostics Limited) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Artiva ARTV|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Ltd.)|Multiplikator Forward P/S verupharma.com (VERU)|Tempest Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake XLO (Xilio Therapeutics Inc)|Enochian BioSciences - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Mural Oncology plc MURA|KAPA: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan OnKure Therapeutics|Rasio rega marang prakiraan pendapatan Curis Inc.|Apollomics Corp (APLM) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S THAR|advanbiomed.com (ADVB) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S GNPX (Genprex, Inc.)|CLDI: Kapitalisasi marang prakiraan pendapatan|SBFM: Multiplikator forward rega marang pendapatan|Xenetic Biosciences - Rasio rega marang pendapatan sing dikarepake|SLRX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Kitov Pharma|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan beigene.com (BGNE)|Multiplikator Forward P/S CKPT|Multiplikator Forward P/S elevationoncology.com (ELEV)|Rasio rega marang prakiraan pendapatan iCAD ICAD|IKNA: Kapitalisasi marang prakiraan pendapatan|Notable Labs, Ltd. - Multiplikator Forward P/S|Viracta Therapeutics (VIRX) - Multiplikator forward rega marang pendapatan|MOR: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NAYA Biosciences Inc (NAYA)|Rasio rega marang prakiraan pendapatan Ascentage Pharma Group Ltd
